Publication|Articles|July 7, 2025
Supplements and Featured Publications
- Targeting Tear Evaporation: How Perfluorohexyloctane Ophthalmic Solution Redefines the Management of Evaporative Dry Eye Disease
Targeting Tear Evaporation: How Perfluorohexyloctane Ophthalmic Solution Redefines the Management of Evaporative Dry Eye Disease
Listen
0:00 / 0:00
Advertisement
This clinical brief is supported by Bausch + Lomb.
This AJMC® Clinical Brief provides a primer on dry eye disease (DED) diagnosis, pathophysiology, and treatment, highlights a DED treatment, and discusses real-world data about patient treatment satisfaction.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029
2
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week
3
Impact of Automated Insulin Delivery on Type 2 Diabetes Measures
4
Dermatology Practices Absorb Rising Prior Authorization Costs
5